Jinglin Zhong

635 total citations
42 papers, 428 citations indexed

About

Jinglin Zhong is a scholar working on Statistics and Probability, Rheumatology and Genetics. According to data from OpenAlex, Jinglin Zhong has authored 42 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Statistics and Probability, 10 papers in Rheumatology and 9 papers in Genetics. Recurrent topics in Jinglin Zhong's work include Statistical Methods in Clinical Trials (11 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Jinglin Zhong is often cited by papers focused on Statistical Methods in Clinical Trials (11 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Rheumatoid Arthritis Research and Therapies (9 papers). Jinglin Zhong collaborates with scholars based in United States, China and Germany. Jinglin Zhong's co-authors include Yi Tsong, Meiyu Shen, Joanne Zhang, Chadi Saifan, Terence Rooney, Mark C. Genovese, Dennis Brinker, Daojun Mo, Fabio P. Nunes and Anabela Cardoso and has published in prestigious journals such as Analytical Biochemistry, Journal of Allergy and Clinical Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Jinglin Zhong

39 papers receiving 422 citations

Peers

Countries citing papers authored by Jinglin Zhong

Since Specialization

Citations

This map shows the geographic impact of Jinglin Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinglin Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinglin Zhong more than expected).

Fields of papers citing papers by Jinglin Zhong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinglin Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinglin Zhong. The network helps show where Jinglin Zhong may publish in the future.

Co-authorship network of co-authors of Jinglin Zhong

This figure shows the co-authorship network connecting the top 25 collaborators of Jinglin Zhong. A scholar is included among the top collaborators of Jinglin Zhong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinglin Zhong. Jinglin Zhong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Estimating heterogeneity of treatment effect in psychiatric clinical trials 2025 ·Journal of Psychiatric Research ·Joshua S. Siegel, Jinglin Zhong, (unknown), (unknown), Stephen V. Faraone, Steven T. Szabo, Kenneth S. Koblan, Seth C. Hopkins	1
2	Kibra knockdown inhibits the aberrant Hippo pathway, suppresses renal cyst formation and ameliorates renal fibrosis in nphp1^KO mice 2025 ·Clinical and Translational Medicine ·Yanlin Yang, (unknown), (unknown), Jinglan Zhang, (unknown), Jinglin Zhong, (unknown), (unknown), Yaqing Liu, Liangzhong Sun	1
3	Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis 2025 ·Journal of Dermatological Treatment ·Jenny E. Murase, Kilian Eyerich, Raj Chovatiya, Hwanhee Hong, Christine Bangert, Lindsay C. Strowd, Mette Deleuran, Amber Reck Atwater, María José Rueda, Hany Elmaraghy, (unknown), Ignasi Pau‐Charles, Fan Emily Yang, Jinglin Zhong, D. Staumont‐Sallé	0
4	Fe2O3 nanoparticles disrupt microstructure and reduce the viscoelasticity of simulated asthma airway mucus for potential airway mucus clearance applications 2025 ·Frontiers in Physiology ·Jinglin Zhong, (unknown), Zhiwei Liu, Kai Ni, (unknown), Yan Pan, Jingjing Li, (unknown), Linhong Deng, Mingzhi Luo	0
5	Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From 11 Trials With Over 3000 Patient-Years of Exposure 2025 ·SKIN The Journal of Cutaneous Medicine ·Linda Stein Gold, Eric L. Simpson, Diamant Thaçi, Alan D. Irvine, Marjolein de Bruin‐Weller, Gaia Gallo, (unknown), Hany Elmaraghy, Jinglin Zhong, (unknown), Ruth Coll, Mark Lebwohl	1
6	Application of hypothetical strategies in acute pain 2024 ·Pharmaceutical Statistics ·Jinglin Zhong, (unknown)	1
7	Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2) 2023 ·Journal of Allergy and Clinical Immunology ·Ellen Sher, Mark Boguniewicz, (unknown), Jinglin Zhong, Amber Reck Atwater, (unknown), Kimberly Siu, Marjolein de Bruin‐Weller, J.M. Carrascosa, Jacob P. Thyssen	2
8	Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo 2023 ·SKIN The Journal of Cutaneous Medicine ·Jenny E. Murase, Mónica Munera‐Campos, Hwanhee Hong, Alain Taı̈eb, Wen‐Hung Chung, Amber Reck Atwater, María José Rueda, Jinglin Zhong, (unknown), Ignasi Pau‐Charles, Mette Deleuran	2
9	Identification of renal cyst cells of type I Nephronophthisis by single-nucleus RNA sequencing 2023 ·Frontiers in Cell and Developmental Biology ·Qianying Wang, (unknown), (unknown), (unknown), (unknown), Lei Wang, Jinglin Zhong, (unknown), Xuefei Gao, Min Li, Albert Ong, (unknown), (unknown)	1
10	Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China 2022 ·Annals of Translational Medicine ·Haisheng Hu, (unknown), (unknown), (unknown), (unknown), Wenxin Wang, Jinglin Zhong, (unknown), Baoqing Sun	4
11	Optimal Sensor Association and Data Collection in Power Materials Warehouse Based on Internet of Things 2021 ·Energies ·(unknown), (unknown), Jinglin Zhong, Guang Chen, (unknown)	2
12	Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5) 2021 ·Journal of the American Academy of Dermatology ·Eric L. Simpson, Seth Forman, Jonathan I. Silverberg, Matthew Zirwas, Emanual Maverakis, George Han, Emma Guttman‐Yassky, (unknown), Robert Bissonnette, Jill Waibel, Fabio P. Nunes, Amy M. DeLozier, (unknown), Margaret Gamalo, Katrin Holzwarth, Orin M. Goldblum, Jinglin Zhong, Jonathan Janes, Kim Papp	106
13	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis 2020 ·The Lancet Rheumatology ·Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi, Gerd R Burmester, Dennis Brinker, Terence Rooney, Jinglin Zhong, Daojun Mo, Chadi Saifan, Anabela Cardoso, Maher Issa, Wen‐Shuo Wu, Kevin Winthrop	55
14	THU0075 EARLY VERSUS DELAYED START OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 TRIAL OF PATIENTS NAÏVE TO METHOTREXATE TREATMENT 2019 ·Annals of the Rheumatic Diseases ·Roy Fleischmann, Michael Schiff, Tore K Kvien, Cem Gabay, Patrick Durez, Anabela Cardoso, Jinglin Zhong, Yunfei Chen, Jennifer K. Workman, Tsutomu Takeuchi	1
15	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies 2018 ·Annals of the Rheumatic Diseases ·Peter C. Taylor, Joel M. Kremer, Paul Emery, Steven H. Zuckerman, Giacomo Ruotolo, Jinglin Zhong, Lei Chen, Sarah Witt, Chadi Saifan, (unknown), James D. Otvos, Margery A. Connelly, William L. Macias, Douglas Schlichting, Terence Rooney, Stephanie de Bono, Iain B. McInnes	47
16	Design considerations for handling dropouts in anti-depressant drug trials 2017 ·Contemporary Clinical Trials ·Jinglin Zhong, Ni A. Khin, Peiling Yang	1
17	Using Tolerance Intervals for Assessment of Pharmaceutical Quality 2014 ·Journal of Biopharmaceutical Statistics ·Xiaoyu Dong, Yi Tsong, Meiyu Shen, Jinglin Zhong	19
18	Multiple Comparisons of Repeated Measured Response: Issues of Assessment of Prolongation of QT Interval in Thorough QT Trials 2010 ·Journal of Biopharmaceutical Statistics ·Yi Tsong, Jinglin Zhong	4
19	Choice of λ‐Margin and dependency of non‐inferiority trials 2007 ·Statistics in Medicine ·Yi Tsong, Mark Levenson, Joanne Zhang, Jinglin Zhong	8
20	An automated homogeneous method for quantifying polysorbate using fluorescence polarization 2004 ·Analytical Biochemistry ·(unknown), (unknown), Marc V. Thorsteinsson, (unknown), (unknown), Jinglin Zhong, Ann L. Lee, Peter DePhillips	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact